| 000 | 01242 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250518033912.0 | ||
| 264 | 0 | _c20191213 | |
| 008 | 201912s 0 0 eng d | ||
| 022 | _a1747-4132 | ||
| 024 | 7 |
_a10.1080/17474124.2019.1605289 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKiesslich, Tobias | |
| 245 | 0 | 0 |
_aHDAC inhibitors in liver cancer: which route to take? _h[electronic resource] |
| 260 |
_bExpert review of gastroenterology & hepatology _cJun 2019 |
||
| 300 |
_a515-517 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
| 650 | 0 | 4 | _aClinical Decision-Making |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aEpigenesis, Genetic _xdrug effects |
| 650 | 0 | 4 |
_aHistone Deacetylase Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aNeureiter, Daniel | |
| 773 | 0 |
_tExpert review of gastroenterology & hepatology _gvol. 13 _gno. 6 _gp. 515-517 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/17474124.2019.1605289 _zAvailable from publisher's website |
| 999 |
_c29595309 _d29595309 |
||